90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

被引：90

作者：

Paganelli, G ^{[1
]}

Bodei, L ^{[1
]}

Junak, DH ^{[1
]}

Rocca, P ^{[1
]}

Papi, S ^{[1
]}

Sierra, ML ^{[1
]}

Gatti, M ^{[1
]}

Chinol, M ^{[1
]}

Bartolomei, M ^{[1
]}

Fiorenza, M ^{[1
]}

Grana, C ^{[1
]}

机构：

[1] European Inst Oncol, Div Nucl Med, I-20141 Milan, Italy

来源：

BIOPOLYMERS | 2002年 / 66卷 / 06期

关键词：

somatostatin analogs; neuroendocrine tumors; radiopeptide therapy; Y-90-DOTA-D-Phe(1)-Try(3)-octreotide (Y-90-DOTATOC);

D O I：

10.1002/bip.10349

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Somatostatin receptors type 2 (sst(2)) are expressed in high concentration on numerous neudoendocrine tumors. The successful use of radiolabeled somatostatin analogs in imaging promoted further studies in utilizing them in radiopeptide therapy. The somatostatin analog [Y-90-DOTA-D-Phe(1)-Try(3)]octreoticle (DOTATOC) (DOTA: 1,4,7,10-tetraazacyclodododecane-N,N',N",N'''-tetraacetic acid) possesses favorable characteristic for its therapeutic use; shows high affinity for sst(2), moderately high affinity for sst(5), and intermediate affinity for sst(3); high hydrophilicity stable and facile labeling with In-111 and Y-90. In this article we report our experience with 90,Y-90-DOTATOC in neuroendocrine tumors. Eighty-seven patients with neuroendocrine tumors were treated with a cumulated activity ranging from 7.4 to 20.2 GBq. Most patients responded with stabilization of disease (48%); however, objective responses were observed in 28% of patients (5% complete response). No major acute reactions were observed tip to the activity of 5.55 GBq per cycle. The dose limiting vas bone marrow, toxicity and the maximal tolerated dose vas defined as 5.48 GBq. (C) 2003 Wiley Periodicals. Inc.

引用

页码：393 / 398

页数：6

共 37 条

[1] Treatment of neuroendocrine GEP tumours with somatostatin analogues - A review [J].